IP Library Granted Patent US 7,091,041
Granted Patent B2
US 7,091,041 · App. 10/627,247 · Granted Aug 15, 2006

Micellar systems

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,091,041
App. No.
10/627,247
Granted
Aug 15, 2006
Kind
B2
Abstract

A complex is described that is deliverable to a cell comprising inserting a nucleic acid or other cargo into a reverse micelle. The reverse micelle has the property to compact the nucleic acid for easier delivery.

Claims (15)

1. A process for delivering a nucleic acid to a cell, comprising:

a) inserting the nucleic acid into a reverse micelle, wherein the reverse micelle comprises a plurality of neutral, negative, or zwitterionic amphipathic molecules containing reactive functional groups;

b) polymerizing two or more of the amphipathic molecules thereby forming a polymerized reverse micelle; and,

c) contacting the cell with the polymerized reverse micelle.

2. The process of claim 1 wherein at least one of the amphipathic molecules contains a labile bond.

3. The process of claim 2 wherein cleavage of the labile bond disrupts the reverse micelle.

4. The process of claim 2 wherein the labile bond consists of a disulfide bond.

5. The process of claim 2 wherein the labile bond consists of a silicon-heteroatom bond.

6. The process of claim 2 wherein the labile bond consists of an amide constructed from a compound having a substructure of succinic anhydride.

7. A reverse micelle containing a nucleic acid formed by the process comprising:

a) inserting the nucleic acid into a negatively-charged, zwitterionic, or neutral reverse micelle, wherein the reverse micelle comprises a plurality of amphipathic compounds containing reactive functional groups capable of participating in a polymerization reaction; and

b) polymerizing two or more of the amphipathic compounds.

8. The complex of claim 7 wherein at least one of the amphipathic molecules contains a biologically labile bond.

9. The complex of claim 8 wherein cleaving the biologically labile bond disrupts the reverse micelle.

10. The complex of claim 7 wherein the nucleic acid is compacted.

Assignments (2)
CHANGE OF NAME Recorded Apr 6, 2009
From: MIRUS BIO CORPORATION
To: ROCHE MADISON INC.
Reel/Frame 022629/0791 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2006
From: MONAHAN, SEAN D.; WOLFF, JON A.; BUDKER, TATYANA, (FOR VLADIMIR BUDKER); HAGSTROM, JAMES E.; SLATTUM, PAUL M.
To: MIRUS BIO CORPORATION
Reel/Frame 018271/0228 →